STANLEY STANLEY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person

LILLY ENDOWMENT INC

(First) 2801 NORTH MERIDIAN STREET

(Last) INDIANAPOLIS IN 46208-0068

(Middle)

2. Issuer Name and Ticker or Trading Symbol

ELILILLY & Co [ LLY ]

3. Date of Earliest Transaction (Month/Day/Year)

08/11/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

Director X 10% Owner

Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

Rule 10b5-1(c) Transaction Indication

☐ This box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>08/11/2023</td>
<td>S</td>
<td>65,457</td>
<td>$528.192</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/11/2023</td>
<td>S</td>
<td>13,181</td>
<td>$529.399</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/11/2023</td>
<td>S</td>
<td>3,817</td>
<td>$530.327</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/11/2023</td>
<td>S</td>
<td>584</td>
<td>$531.335</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>08/11/2023</td>
<td>S</td>
<td>65,457</td>
<td>$528.192</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/11/2023</td>
<td>S</td>
<td>13,181</td>
<td>$529.399</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/11/2023</td>
<td>S</td>
<td>3,817</td>
<td>$530.327</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/11/2023</td>
<td>S</td>
<td>584</td>
<td>$531.335</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Explanation of Responses:

1. The price reported in Column 5 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.00 to $528.995, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), and (4) to this Form 4.

2. The price reported in Column 6 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $529.00 to $529.99, inclusive.

3. The price reported in Column 7 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $530.00 to $530.95, inclusive.

4. The price reported in Column 8 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $531.0937 to $531.57, inclusive.

/s/ Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc.

08/14/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.